The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center

Abstract Background Myelodysplastic syndrome (MDS) is a rare disease in children and the treatment option before the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rarely reported. Our main objective was to report our single-center experience with the DNA-hypomethylating agent, de...

Full description

Bibliographic Details

Published in:	BMC Pediatrics
Main Authors:	Junyan Gao, Yixin Hu, Li Gao, Peifang Xiao, Jun Lu, Shaoyan Hu
Format:	Article
Language:	English
Published:	BMC 2022-05-01
Subjects:	Pediatric myelodysplastic syndrome Allogeneic hematopoietic stem cell transplantation Decitabine Minimally myelosuppressive regimen Overall survival
Online Access:	https://doi.org/10.1186/s12887-022-03376-1